IDIBELL Participates in the Creation of a Bioinformatics Platform to Promote Education
News Feb 18, 2013
IDIBELL, along with nine other research institutions in the field of biomedicine, three Catalan universities, the Barcelona Supercomputing Center-Centro National de Supercomputación (BSC-CNS) and BioCat signed on February 14th an agreement for the creation of the Bioinformatics Barcelona (BiB), a platform which aims is to turn the Barcelona area as global reference center in bioinformatics, through cooperation between universities, research centers, and other public and private entities.
Bioinformatics is an area of research in applied computer science and information technology used for the treatment of biological data. BiB promoters consider this area as strategic science that makes sense of the vast amounts of biological data generated. So BiB proposes to boost this area of specialization that is necessary in all areas of life sciences and has a profound impact on fields as diverse as human health, the food industry, the environment and biotechnology.
Promoting high-level postgraduate studies
It seeks to take advantage of the critical mass of internationally renowned researchers in bioinformatics in the Barcelona area to promote high-level postgraduate studies, including the training of new professionals, and to develop scientific and transfer knowledge initiatives.
The agreement is a commitment between the different institutions to develop, within six months, the strategic plan to formally constitute the initiative. The task of preparing this plan will be led by Anna Ripoll, Professor of Architecture and Computer Technology and rector at the Autonomous University of Barcelona (UAB), who will be its executive chairman. Ferran Sanz, head of Biomedical Informatics at the UPF, will be its scientific director.
LifeArc and Milner Therapeutics Institute Announce a New Partnership in AI for Target DiscoveryNews
LifeArc®, the UK-based medical research charity, and the Milner Therapeutics Institute at the University of Cambridge, today announced a new partnership to identify and validate new drug targets in immuno-oncology and respiratory diseases.READ MORE
Drug-like Compounds Reverse Chemotherapy Failure for 3 Aggressive CancersNews
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers -- ovarian, prostate and breast.READ MORE
Algorithm Unearths Over 1000 Antibiotic Proteins in a Few HoursNews
The algorithm identified 10 times more peptide variations than all previous discoveries combined, aiding the hunt for new antibiotics.READ MORE